Overview: HLA-ABC Class I Typing TestIntroduction: The HLA-ABC Class I Typing Test types HLA-ABC antigens to assess transplant compatibility, preventing rejection. Aligned with 2023 ASHI guidelines, it uses PCR for high specificity, aiding in transplant screening. This test is critical for guiding transplant decisions, matching donors, and improving outcomes in molecular pathology for patients undergoing organ or bone marrow transplantation.
Other Names: HLA-ABC Assay, Class I HLA Typing Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-ABC typing improved in the 2000s, enhancing compatibility assessment.
Purpose: Assesses HLA-ABC for transplant compatibility, guides donor matching, and prevents rejection in patients.
Test Parameters: 1. HLA-ABC Antigens
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of transplants, autoimmune diseases, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document history of transplants, autoimmune diseases, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility implications, and potential need for transplant planning.
Procedural Considerations: Uses PCR to type HLA-ABC antigens. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for transplant compatibility.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: HLA-ABC typing ensures donor-recipient compatibility, reducing rejection risk. Mismatches guide immunosuppression planning.
Specialist Consultation: Consult a transplant immunologist or hematologist for result interpretation and transplant planning.
Additional Supporting Tests: HLA-DR typing, antibody screening, or crossmatch testing to assess transplant compatibility.
Test Limitations: Limited to HLA-ABC; other loci may need testing. Clinical correlation is needed.
References: ASHI HLA Guidelines, 2023; Human Immunology, Tait BD, 2022.
